Skip to content

Viridian Therapeutics, Inc. VRDN Total Cost of Revenue

Discontinued — last reported Q4 '16

Total Cost of Revenue at other companies

Amgen logo
AmgenAMGN
$2.74B-7.5%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$93.58M+28.1%
TG Therapeutics logo
TG TherapeuticsTGTX
$33.51M+116%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$9.94M+277%
ALN
Alnylam PharmaceuticalsALNY
$207.52M+196%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$8.11B+10.2%

Other financials

Income statement

See full
Revenue$141.0K+95.8%
Operating income-$116.2M-23.8%
Net income-$104.9M-20.7%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$176.3M+51.7%
Total debt$36.8M+59.4%
Total equity$636.0M+5.2%
Total assets$789.0M+19.4%

Cash flow

See full
Operating cash flow-$119.7M-29.1%
CapEx$23.0K-73.3%
Free cash flow-$119.7M-29.0%

Valuation

See full
Market cap$1.91B+82.0%
Enterprise value$1.77B+85.0%
P/S26.9×-3,445×

Profitability

See full
Gross margin36.3%
Operating margin-543.9%-271pp
Net margin-508.5%-254pp
FCF margin-428.4%-214pp

Returns & leverage

See full
Return on equity-58.1%+7.9pp
Debt / equity0.1×0.0×
Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CostOfRevenue.

The official record: Viridian Therapeutics, Inc.’s 10-K, filed March 24, 2017, on SEC EDGAR. View the filing →

Questions, answered.

What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.